This antibody recognizes a 67 kDa transmembrane protein, which is identified as CD5. It is found on 95 % of thymocytes and 72 % of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in Tcell areas. CD5 antibody is a pan Tcell marker that also reacts with a range of neoplastic Bcells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10 %) of diffuse large Bcell lymphoma. Aberrant expression is useful in making a diagnosis of mature Tcell neoplasms. CD5 antibody detection is diagnostic in CLL/SLL within a panel of other Bcell markers, especially one that includes anti-CD23. CD5 antibody is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, it can be used in distinguishing thymic carcinoma (+) from thymoma (-). It does not react with granulocytes or monocytes.
Aufreinigung
Protein G affinity chromatography
Immunogen
Stimulated human leukocytes were used as the immunogen for this CD5 antibody.
CD5
Reaktivität: Human
FACS
Wirt: Maus
Monoclonal
L17F12
PE
Applikationshinweise
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD5 antibody to be titered up or down for optimal performance.\. Functional Testing: order BSA/azide-free format,FACS: 0.5-1 μg/million cells,IF: 0.5-1 μg/mL
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Konservierungsmittel
Azide free
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store the CD5 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Target
CD5
Andere Bezeichnung
CD5
Hintergrund
This antibody recognizes a 67 kDa transmembrane protein, which is identified as CD5. It is found on 95 % of thymocytes and 72 % of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in Tcell areas. CD5 antibody is a pan Tcell marker that also reacts with a range of neoplastic Bcells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (~10 %) of diffuse large Bcell lymphoma. Aberrant expression is useful in making a diagnosis of mature Tcell neoplasms. CD5 antibody detection is diagnostic in CLL/SLL within a panel of other Bcell markers, especially one that includes anti-CD23. CD5 antibody is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, it can be used in distinguishing thymic carcinoma (+) from thymoma (-). It does not react with granulocytes or monocytes.